

1 ***SYNE1* gene novel variant is associated with myocardial infarction in young people with**
2 **a family history of premature atherosclerosis.**

3 Michał Ambroziak MD, PhD, Assoc. Prof. ^a, Jakub Franke MD ^{b, c}, Anna Wójcicka MD, PhD,
4 Assoc. Prof. ^{b, d}, Monika Kolanowska MD, PhD ^{b, e}, Andrzej Budaj MD, PhD, Prof. ^a

5

6 ^a Department of Cardiology, Centre of Postgraduate Medical Education, Grochowski
7 Hospital; Warsaw, Poland

8 ^b Warsaw Genomics; Warsaw, Poland

9 ^c II Department of Radiology, Medical University of Warsaw, Warsaw, Poland

10 ^d Fundacja Wiedzieć Wiecej; Warsaw, Poland

11 ^e Department of Tumor Biology and Genetics, Medical University of Warsaw; Warsaw,
12 Poland

13

14 **Short title:** *SYNE1* gene variant in premature atherosclerosis.

15

16 **Corresponding author:**

17 Michał Ambroziak; e-mail: madaba@op.pl

18 Department of Cardiology, Centre of Postgraduate Medical Education, Grochowski Hospital,
19 04-730 Warsaw, Grenadierów 51/59, phone/fax: +48 22 810-17-38

20 orcid.org/0000-0002-3172-0719

21

22 **Word count:** 4261
Word count: 4261

1 **Abstract**

2 Aim. The aim of the study was to investigate the role of genetic variants in young patients
3 (aged <50 years) with myocardial infarction (MI) and a family history of premature
4 atherosclerosis.

5 Methods and Results. The studied group consisted of 70 patients aged 26-49 (mean 43.1, SD
6 ± 4.3), 17 women and 53 men, with MI and with a family history of premature atherosclerosis,
7 defined as MI or ischaemic stroke in first-degree relatives at age <65 years in women or <55
8 years in men. The total DNA was extracted from the peripheral blood samples. The targeted
9 enrichment library was prepared and analyzed using the Next-Generation Sequencing method.
10 Statistical analyses were performed using the R software package (<http://www.r-project.org/>).
11 The results of sequencing were compared to data from the reference control population
12 consisting of 597 people with no history of MI (418 women, 179 men) aged 18-83 (mean
13 40.5, SD ± 12.4) as a whole and after matching with a studied group by age and gender in a
14 proportion 1:3 (210 people, 51 women, 159 men, aged 18-77, mean 42.1, SD ± 10.6) using
15 Propensity Score Matching. Risks associated with detected variants were evaluated using
16 Fisher's exact test based on the allelic frequencies of variants in both groups.

17 *SYNE1* gene variant rs36215567 (NM_182961.4: c.20396+22A>G) occurs with a
18 significantly higher incidence in the studied group when compared to the control population
19 with OR 4.80 95%CI 1.43-14.45 (p=0.005) as well as when compared to the control
20 population matched by age and gender OR 9.31 95%CI 1.64-95.41 (p=0.004). There were no
21 statistically significant differences in the incidence of variants related to familial
22 hypercholesterolemia such as *LDLR* c.667G>A, *PCSK9* c.658-36G>A, and *APOB*
23 c.12382G>A between both cohorts.

1 Conclusion. A novel variant of the *SYNE1* gene is associated with myocardial infarction in
2 young patients with a family history of premature atherosclerosis.

3

4

5 **Lay summary**

- 6 • The wide use of genetic information to predict coronary artery disease (CAD)
7 development and incidence, particularly important in young people, still requires
8 investigation before clinical implementation.
- 9 • A novel variant of the *SYNE1* gene is associated with myocardial infarction (MI) in
10 young patients with a family history of premature atherosclerosis.
- 11 • Although, the role of *SYNE1* in the maintenance of proper function of the cardiac
12 muscles and coronary arteries remains still under examination the result of this study
13 open a new opportunity to use the *SYNE1* gene variant in genetic risks MI scores.

14

15

16 **Key-words**

17 *SYNE1*, myocardial infarction at a young age, premature coronary artery disease,
18 cardiovascular disease family history

19

20

21

1 **1. Introduction**

2 Cardiovascular diseases (CVDs) are the leading cause of death globally. As the World
3 Health Organization (WHO) reports, an estimated 17.9 million people died from CVDs in
4 2019, representing 32% of all global deaths [1]. Ischemic heart disease (IHD) rose from the
5 third to the first leading global cause of premature mortality, measured by years of life lost
6 (YLL), between 1990 and 2019 [2]. In the EUROASPIRE V study, which involved people
7 with confirmed coronary artery disease (CAD), up to 9% of the studied population were
8 patients aged <50 years [3]. According to the Framingham study, the MI incidence for a 10-
9 year follow-up differs between the age groups - it was 12.9, 38.2, and 71.2 per 1000 in males
10 and 2.2, 5.2, and 13.0 per 1000 in females in the age groups of 30–34, 35–44, and 45–54
11 years, respectively [4].

12 There are differences in risk factor profiles between individuals who experienced the first
13 myocardial infarction at a very young (≤ 40 years) and a young (age 41-50 years) age. When
14 compared with young patients, very young individuals are more likely to use both marijuana
15 and cocaine [5]. Conversely, patients aged 41 to 50 years are more likely to be diagnosed with
16 hypertension or peripheral vascular disease, use alcohol, and have a higher 10-year
17 atherosclerotic cardiovascular disease risk score. Nevertheless, the overall burden of
18 traditional risk factors was similar between very young and young patients.

19 The INTERHEART study carried out in 52 countries around the world on more than 12
20 thousand patients showed that smoking, lipid abnormalities, hypertension, and diabetes as
21 more significant risk factors for MI in younger than in older patients [6]. Apart from those
22 factors, a family history of premature IHD and genetic factors seem to be especially important
23 in young people with MI.

1 According to the European Society of Cardiology guidelines for CVD prevention, the
2 routine use of genetic risk scores is not yet recommended [7]. There is no consensus regarding
3 which genes and corresponding single nucleotide polymorphisms should be included, and
4 whether to use risk factor-specific or outcome-specific polygenic risk scores (PRS) [8]. The
5 addition of a PRS for CAD to pooled cohort equations seems to be associated with a
6 statistically significant, yet modest, improvement in the predictive accuracy for incidents of
7 CAD and improved risk stratification for only a small proportion of individuals [9]. Among
8 young adults from the CARDIA study (Coronary Artery Risk Development in Young Adults)
9 and Framingham Offspring Study, PRS improved model discrimination for coronary
10 atherosclerosis, but improvements were smaller than those associated with modifiable risk
11 factors [10].

12 Nevertheless, there is no doubt that genetic information is a valuable complement to
13 traditional factors in CAD risk stratification, particularly in young people. The wide use of
14 genetic information to predict CAD development and incidence still requires investigation
15 before clinical implementation. The group of special interest is a population of young people
16 with CAD and a family history of premature IHD, defined as MI or ischemic stroke in first-
17 degree relatives at age <55 years in men and < 65 years in women [11]. Thus, the aim of our
18 study was to investigate the role of genetic variants in this very special population – young
19 patients with MI and a family history of premature IHD.

20

21 **2. Subjects and methods**

22 2.1. Patients

23 The studied group consisted of 70 patients with MI aged 26-49 (mean 43.1, SD \pm 4.3;
24 17 women and 53 men), admitted to the Department of Cardiology, Centre of Postgraduate

1 Medical Education, Grochowski Hospital in years 2007-2019. All patients had been
2 diagnosed MI based on clinical presentation, ecg and biochemical criteria, including MI with
3 ST elevation (STEMI) in 18 cases (25.7%) and MI without ST elevation (NSTEMI) in 52
4 cases (74.3%) and had a family history of premature atherosclerosis, defined as MI or
5 ischemic stroke in first-degree relatives at age <65 years in women or <55 years in men. All
6 patients, except 2 (no consent), had performed coronary angiography revealing 1-vessel
7 coronary artery disease (VCAD) in 33 patients (47.1%), 2-VCAD in 17 patients (24.3%), and
8 3-VCAD in 20 patients (28.6%); Table 1. The mean left ventricular ejection fraction (LVEF)
9 was 51.8% (SD \pm 8.0).

10 There were 15 (21.4%) participants of the study with university degree, 46 (65.7%)
11 with completed high school education and 7 (10%) with completed elementary school
12 education (2 patients have not provided information). Regarding a type of job – there were 37
13 (52.8%) blue collar workers, 23 (32.9%) white collar workers, 3 (4.3%) unemployed and 2
14 (2.9%) people on pension (5 patients have not provided information). Regarding marriage
15 status – there were 40 (57.1%) married people in the study, 18 (25.7%) single, 6 (8.6%)
16 divorced, 2 widows and 1 widower (4.3%); 3 patients have not provided information.

17 All participants of the study provided written informed consent. The Ethical
18 Committee of the Centre of Postgraduate Medical Education approved the study protocol. The
19 investigation conforms to the principles outlined in the Declaration of Helsinki.

20 The results of sequencing were compared to data from the reference Warsaw
21 Genomics control population consisting of 597 people with no history of MI (418 women,
22 179 men) aged 18-83 (mean 40.5, SD \pm 12.4) as a whole and after matching using Propensity
23 Score Matching with a studied group by age and gender in a proportion 1:3 (210 people, 51
24 women and 159 men, aged 18-77, mean 42.1, SD \pm 10.6).

1

2 2.2 Anthropometric, clinical and biochemical analysis

3 BMI was calculated as weight (kg)/height (m²). Depression and smoking status,
4 including duration and intensity (cigarette number per day) of smoking, were assessed based
5 on the patient's history. Hypertension was assessed based on the medical history and
6 treatment or on a mean value of two measurements of systolic (SBP) and diastolic (DBP)
7 blood pressure performed after at least 5 minutes sitting, made in 5 minute intervals.
8 Hypertension was defined as values ≥ 140 mmHg SBP and/or ≥ 90 mmHg DBP according to
9 ESH/ESC (European Society of Hypertension, European Society of Cardiology) guidelines.
10 Diabetes mellitus was assessed based on the medical history and treatment or based on fasting
11 plasma glucose ≥ 126 mg/dl or ≥ 200 mg/dl in oral glucose tolerance test according to WHO
12 and ADA (American Diabetes Association) guidelines.

13 Blood samples were collected on admission and the next morning. Biochemical
14 analyses, including glucose, total, HDL, and LDL cholesterol as well as triglycerides (TG)
15 plasma concentrations were performed in fasting blood samples by standard enzymatic
16 methods using COBAS INTEGRA 800 reagents and equipment (Roche Diagnostics GmbH).

17

18 2.3 Genotyping

19 Total DNA was extracted from whole peripheral blood samples. The extraction was
20 performed on Maxwell® RSC 48 Instrument (Promega) using the Maxwell® RSC Blood
21 DNA Kit, according to the protocol. The targeted enrichment library was prepared and
22 analyzed using the Next-Generation Sequencing (NGS) method. The total DNA input for
23 NGS libraries was 35 ng. The sample libraries were prepared on Biomed i7 (Beckam and

1 Coulter) with the use of Kapa HyperPlus protocol (Roche Diagnostics). The concentration and
2 quality of the libraries were subsequently verified on SpectraMax (Molecular Devices) and
3 TapeStation 4200 and subjected to the hybridization capture (NimbleGen EZ SeqCap, Roche
4 Diagnostics). The hybridization was conducted according to the Roche protocol. The size,
5 concentration, and quality of obtained final NGS library were confirmed by TapeStation 4200
6 and Quantus (Promega). The samples were sequenced on the Hiseq4000 (Illumina), 2x150
7 cycles.

8

9 2.4 Statistical analysis

10 Statistical analyses were performed using the R software package ([http://www.r-](http://www.r-project.org/)
11 [project.org/](http://www.r-project.org/)). Risks associated with detected variants were evaluated using Fisher's exact test
12 based on the allelic frequencies of variants in both groups.

13

14 3. Results

15 3.1 Anthropometric, biochemical and clinical characteristics of studied and control
16 groups.

17 The mean BMI in the studied group was 28.8 kg/m² (SD ±3.5), total cholesterol level
18 202.3 mg/dl (SD ±3.5), HDL 40.6 mg/dl (SD ±9.6), LDL 124.0 mg/dl (SD ±28.9),
19 triglycerides 164.4 mg/dl (SD ±63.5), glucose 108.3 mg/dl (SD ±19.9) and creatinine 0.9
20 mg/dl (SD ±0.2); Table 2. Regarding other risk factors 63 patients (90%) were smokers (mean
21 24.1 pack-years, SD ±13.0), 44 (62.8%) had hypertension, 11 (15.7%) had diabetes mellitus,
22 and 8 (11.4%) had depression; Table 3.

1 The mean BMI in the control group was 24.5 kg/m², (SD ± 4.8) with 176 smokers
2 (29,5%). The mean BMI in the control group matched with a studied group by age and gender
3 was 26.08 kg/m² (SD ± 4.3) and this group included 62 smokers (29,5%).

4

5 3.2 Next-Generation Sequencing

6 The sequencing encompassed the coding sequences of 159 genes with 40 nucleotide
7 intronic flanks. Low quality variants were removed, and the variants of the allele count
8 greater or equal to 5 in the MI group were considered in further analysis. Variants were
9 narrowed down to those classified as at least variants of unknown significance according to
10 the bioinformatic algorithm. This resulted in identification of four variants in *LDLR*, *SYNE1*,
11 *PCSK9* and *APOB* genes. Allelic count of these SNPs was assessed in the control group.
12 Furthermore, for each variant Hardy-Weinberg equilibrium was tested in the control
13 population showing (p>0.05). Fisher's exact test was used to check for differences in allelic
14 frequencies in both groups; Table 4.

15 Sequencing and statistical analysis performed in the MI patients and healthy controls
16 revealed the presence of a single variant in the *SYNE1* gene, with an enriched abundance
17 within the patients. We did not observe any statistically significant differences between the
18 frequency of other variants, including known, pathogenic variants related to familial
19 hypercholesterolemia (FH) as well as variants of unknown significance of FH related genes:
20 *LDLR* c.667G>A, *PCSK9* c.658-36G>A, and *APOB* c.12382G>A.

21 *SYNE1* gene variant rs36215567 (NM_182961.4: c.20396+22A>G) is statistically
22 significantly more prevalent in the studied group in comparison to the control population with
23 OR 4.80, 95%CI 1.43-14.45 (p=0.005) as well as when compared to the control population
24 matched by age and gender OR 9.31, 95%CI 1.64-95.41(p=0.004); Figure 1.

1 Considering that the study group differed significantly in BMI and the number of
2 smokers ($p < 0.001$) when compared with both unmatched and matched control population the
3 multivariable logistic regression model was created. The model included smoking status, BMI
4 and presence of *SYNE1* rs36215567. The model confirmed this SNP to be an independent risk
5 factor for premature MI with OR 13,86 95%CI 1.64 – 117.45 ($p = 0.016$); Table 5.

6

7 **4. Discussion**

8 The main aim of this study was to identify single variants predisposing to MI at a
9 young age as the genetic background seems to be particularly important in the pathogenesis of
10 CAD in this group. In our previous study we revealed that the younger age of patients with
11 myocardial infarction is associated with a higher number of relatives with a history of
12 premature MI/ischaemic stroke [12].

13 Numerous evidence indicates that CAD at a young age is associated with a genetic
14 background. A significant enrichment of increased polygenic score has been noted among
15 patients with early-onset (age ≤ 55 years) MI as compared with population-based controls,
16 with median polygenic score among patients in the 72nd percentile [13]. Both familial
17 hypercholesterolemia mutations and high polygenic score were associated with more than
18 three-fold increased odds of early-onset MI. Monogenic familial hypercholesterolemia or a
19 high genome-wide polygenic score confer to a 4- to 5-fold relative risk, which suggests that
20 assessment for familial hypercholesterolemia mutations and genome-wide polygenic scores
21 could be very useful for risk prediction, especially when combined with traditional risk
22 factors for CAD [14].

23 Using data from the UK Biobank on 306,654 individuals without a history of CVD
24 and not receiving lipid-lowering treatments, Sun L et al. calculated risk discrimination and

1 reclassification upon addition of PRSs to risk factors in a conventional risk prediction model
2 (i.e., age, sex, systolic blood pressure, smoking status, history of diabetes, and total and high-
3 density lipoprotein cholesterol) [15]. The addition of information on PRSs increased the C-
4 index by 0.012 (95% CI 0.009–0.015) and resulted in continuous net reclassification
5 improvements – among people at intermediate (5% to <10%) 10-year CVD risk could help
6 prevent 1 additional CVD event for approximately every 340 individuals screened. Such a
7 targeted strategy could help prevent 7% more CVD events than conventional risk prediction
8 alone. Moreover, it has been shown lastly, that adding PRS to clinical risk assessment has
9 significantly improved identification people who experience a serious CVD event, especially
10 in young age – among people aged 40-54 years clinical risk assessment alone identified
11 26.0% (95% CI: 16.5%–37.6%) of those who developed a major CVD event, while the
12 combination of clinical and genetic approach identified 38.4% (95% CI: 27.2%–50.5%) [16].

13 In this study, we used the Next-Generation Sequencing to identify possible MI-related
14 genetic variants in young patients. Since the familial aggregation of MI is an independent risk
15 factor for the disease, we decided to perform an analysis using a panel of 159 genes related to
16 various cardiovascular disorders, including 26 genes that are known to be involved in
17 myopathies and dyslipidemias. Interestingly, our study did not show any statistically
18 important difference in frequencies of variants commonly associated with dyslipidemias
19 between the two studied groups [17]. We identified a single genetic variant in the *SYNE1*
20 gene, whose prevalence was higher in MI patients. The rs36215567 (NM_182961.4:
21 c.20396+22A>G) variant is located in an intron of a gene, possibly altering splicing of the
22 *SYNE1* gene and resulting in altered activity of the translated protein, though the effect of this
23 variant on the production of different *SYNE1* transcripts has not been described. It is a rare
24 variant occurring at the frequency of 0.89% in the European population (1000 genomes
25 project).

1 *SYNE1* (Spectrin Repeat Containing Nuclear Envelope Protein 1; Nesprin1) gene is a
2 protein-coding gene located in a long arm of chromosome 6, position 6q25.2. Its protein is a
3 member of the spectrin family of structural proteins that link the nuclear plasma membrane to
4 the actin cytoskeleton. It is expressed in numerous tissues, but it has mainly been mapped to
5 the aortic vascular smooth muscle cells and heart [18]. *SYNE1* aberrances were mainly
6 associated with arthrogyrosis and muscular dystrophies (Online Mendelian Inheritance in
7 Men) but more recent papers identified its involvement in dilated cardiomyopathy [19, 20].
8 Interestingly, this association results mainly from the presence of alternatively spliced gene
9 isoforms. *SYNE1* has been shown also to be involved in the angiotensin-II-induced cardiac
10 hypertrophy by miR-525-5p / specific protein transcription factor SP1 axis [21].

11 Moreover, a recent study revealed an important role of *SYNE1* in cell regeneration and
12 showed that its levels decrease with age possibly leading to a decrease in cardiac function
13 [22]. Thus, even though the exact role of *SYNE1* protein in cardiovascular homeostasis is still
14 largely unknown, a growing number of data suggest its role in the maintenance of proper
15 function of the cardiac and arterial muscles.

16 There are also available data indicating a possible role of *SYNE1* variants (although
17 others than shown in our study) in the development of CAD by the involvement in the
18 morbidity of hypercholesterolemia and hypertriglyceridemia through gene-gene and SNP-
19 SNP interactions [23]. It suggests, considering the results of our study, other potential gene-
20 gene interactions including *SYNE1* gene variants in the pathogenesis of CAD.

21 The main limitation of this study is the relatively small number of participants. The
22 assumptions of the study, including young patients with MI and a family history of premature
23 atherosclerosis, make this population very unique, but at the same time difficult to enlarge. On
24 the other hand, the high homogeneity of the groups, limited to the Polish Caucasian

1 population, may be important in the context of potential population and racial differences in
2 the pathogenesis of CAD, especially when analyzing genetic risk factors. Moreover, this the
3 first report regarding potential role of *SYNE1* in premature CAD which means that there are
4 no similar data in wide databases yet as well as functional studies carried out to elucidate
5 potential mechanisms. However, this strengthens the value of our finding.

6 In conclusion: a novel variant of the *SYNE1* gene is associated with myocardial
7 infarction in young age patients with a family history of premature atherosclerosis.
8 Nevertheless, the wide use of such genetic information to predict CAD development and
9 incidences still requires further investigation including wide genetic and functional studies
10 before clinical implementation.

11

12

13

14 **Source of Funding**

15 This work was supported by Grant No. 501-1-10-14-20 from the Centre of Postgraduate
16 Medical Education, Warsaw, Poland.

17

18 **Disclosures**

19 All authors declare no conflict of interest.

20

21

22

1 **References**

- 2 1. [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))
- 3 2. Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme
4 AK, Buxton AE, Carson AP, Commodore-Mensah Y et al. Heart Disease and Stroke
5 Statistics—2022 Update: A Report From the American Heart Association. *Circulation*
6 2022;145:e153–e639.
- 7 3. Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, Maggioni A,
8 Marques-Vidal P, Jennings C, Abreu A et al. Lifestyle and impact on cardiovascular
9 risk factor control in coronary patients across 27 countries: Results from the European
10 Society of Cardiology ESC-EORP EUROASPIRE V registry. *Eur J Prev Cardiol*
11 2019;26:824-835.
- 12 4. Kannel WB Abbott RD. Incidence and prognosis of unrecognized myocardial
13 infarction. An update on the Framingham study. *NEJM* 1984;311:1144-7.
- 14 5. Yang J, Biery DW, Singh A, Divakaran S, DeFilippis EM, Wu WY, Klein J, Hainer J,
15 Ramsis M, Natarajan P et al. Risk Factors and Outcomes of Very Young Adults Who
16 Experience Myocardial Infarction: The Partners YOUNG-MI Registry. *Am J Med.*
17 2020;133:605–612.
- 18 6. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanus F, McQueen M, Budaj A,
19 Pais P, Varigos J et al. INTERHEART Study Investigators. Effect of potentially
20 modifiable risk factors associated with myocardial infarction in 52 countries (the
21 INTERHEART study): case-control study. *Lancet*, 2004;364:937–952.
- 22 7. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A,
23 Biffi A, Boavida JM, Capodanno D et al. ESC National Cardiac Societies; ESC

- 1 Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease
2 prevention in clinical practice: Developed by the Task Force for cardiovascular
3 disease prevention in clinical practice with representatives of the European Society of
4 Cardiology and 12 medical societies with the special contribution of the European
5 Association of Preventive Cardiology (EAPC). *European Heart Journal*
6 2021;42:3227–3337.
- 7 8. Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores.
8 *Hum Mol Genet.* 2019;28:R133–R142.
- 9 9. Elliott J, Bodinier B, Bond TA, Chadeau-Hyam M, Evangelou E, Moons KGM,
10 Dehghan A, Muller DC, Elliott P, Tzoulaki I. Predictive Accuracy of a Polygenic Risk
11 Score–Enhanced Prediction Model vs a Clinical Risk Score for Coronary Artery
12 Disease. *JAMA* 2020;323: 636-645.
- 13 10. Welss QS, Bagheri M, Aday AW, Gupta DK, Shaffer ChM, Wei W-Q, Vaitinadin NS,
14 Khan SS, Greenland Ph, Wang TJ et al. Polygenic Risk Score to Identify Subclinical
15 Coronary Heart Disease Risk in Young Adults. *Circ Genom Precis Med*
16 2021;14:e003341.
- 17 11. Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, Levy D, Murabito JM, Wang TJ,
18 Wilson PWF, O'Donnell ChJ. Parental cardiovascular disease as a risk factor for
19 cardiovascular disease in middle-aged adults: a prospective study of parents and
20 offspring. *JAMA* 2004;291:18.
- 21 12. Ambroziak M, Niewczas-Wieprzowska K, Maicka A, Budaj A. Younger age of
22 patients with myocardial infarction is associated with a higher number of relatives
23 with a history of premature atherosclerosis. *BMC Cardiovasc Disord* 2020 11;20:410.

- 1 13. Khera AV, Chaffin M, Zekavat SM, Collins RL, Roselli C, Natarajan P, Lichtman JH,
2 D'Onofrio G, Mattera J, Dreyer R et al. Whole genome sequencing to characterize
3 monogenic and polygenic contributions in patients hospitalized with early-onset
4 myocardial infarction. *Circulation* 2019;139:1593–1602.
- 5 14. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P,
6 Lander ES, Lubitz SA, Ellinor PT et al. Genome-wide polygenic scores for common
7 diseases identify individuals with risk equivalent to monogenic mutations. *Nat Genet*
8 2018;50(9): 1219–1224.
- 9 15. Sun L, Pennells L, Kaptoge S, Nelson ChP, Ritchie SC, Abraham G, Arnold M, Bell
10 S, Bolton T, Burgess S et al. Polygenic risk scores in cardiovascular risk prediction: A
11 cohort study and modeling analyses. *PLoS Med* 2021;18:e1003498.
- 12 16. Samani NJ, Beeston E, Greengrass Ch, Riveros-McKay F, Debiec R, Lawday D,
13 Wang Q, Budgeon ChA, Braund PS, Bramley R et al. Polygenic risk score adds to a
14 clinical risk score in the prediction of cardiovascular disease in a clinical setting.
15 *European Heart Journal* 2024;00:1–9.
- 16 17. Ranthe MF, Petersen JA, Bundgaard H, Wohlfahrt J, Melbye M, Boud HA. A Detailed
17 Family History of Myocardial Infarction and Risk of Myocardial Infarction – A
18 Nationwide Cohort Study. *PLOS ONE* 2015;10:e0125896.
- 19 18. Zhang Q, Skepper JN, Yang F, Davies JD, Hegyi L, Roberts RG, Weissberg PL, Ellis
20 JA, Shanahanl CM. Nesprins: a novel family of spectrin-repeat-containing proteins
21 that localize to the nuclear membrane in multiple tissues. *J. Cell Sci* 2001;114:4485-
22 4498.
- 23 19. OMIM, www.omim.org, entry # 608441

- 1 20. Zhou C, Li C, Zhou B, Sun H, Koullourou V, Holt I, Puckelwartz MJ, Warren DT,
2 Hayward R, Lin Z et al. Novel nesprin-1 mutations associated with dilated
3 cardiomyopathy cause nuclear envelope disruption and defects in myogenesis. *Hum*
4 *Mol Genet* 2017;26:2258-2276.
- 5 21. Wang Y, Cao R, Yang W, Qi B. SP1-SYNE1-AS1-miR-525-5p feedback loop
6 regulates Ang-II-induced cardiac hypertrophy. *J Cell Physiol* 2019;234:14319-14329.
- 7 22. Dong J, Liu J, Wen Y, Tobin SW, Zhang C, Zheng H, Huang Z, Feng Y, Zhang D, Liu
8 S. Down-Regulation of Lnc-CYP7A1-1 Rejuvenates Aged Human Mesenchymal
9 Stem Cells to Improve Their Efficacy for Heart Repair Through SYNE1. *Front Cell*
10 *Dev Biol* 2020;8:600304.
- 11 23. Zheng PF, Yin RX, Liu ChX, Deng GX, Guan YZ, Wei BL. SYNE1-QK1 SNPs, G ×
12 G and G × E interactions on the risk of hyperlipidaemia. *J Cell Mol Med*
13 2020;24:5772-5785.

14
15
16
17
18
19
20
21
22

1 **Figures**

2

3 **Figure 1**

4 *SYNE1* gene variant rs36215567 (NM_182961.4: c.20396+22A>G) *LDLR* c.667G>A,
5 *PCSK9* c.658-36G>A, and *APOB* c.12382G>A incidence in the studied group (70 patients)
6 compared to the control population matched by age and gender (210 people); Fisher's exact
7 test.

8 *APOB* – apolipoprotein B gene, CI – confidence intervals, G – guanine, *LDLR* – low density
9 lipoprotein receptor gene, OR – odds ratio, *PCSK9* – proprotein convertase subtilisin/kexin
10 type 9 gene, SNP – single nucleotide polymorphism, *SYNE1* - spectrin repeat containing
11 nuclear envelope protein 1 gene.

12

13

14

15

16

17

18

19

20

21

1 **Tables**

2

3 Table 1

4 Clinical and haemodynamic characteristics of studied group (70 patients).

5 CAD – coronary artery disease, LVEF – left ventricle ejection fraction, NSTEMI – non-ST
6 elevation myocardial infarction, SD – standard deviation, STEMI – ST elevation myocardial
7 infarction.

8

9 Table 2

10 Anthropometric and biochemical characteristics of studied group (70 patients).

11 BMI – body mass index, HDL – high density lipoprotein, LDL – low density lipoprotein, SD
12 – standard deviation.

13

14 Table 3

15 CAD risk factors in studied group (70 patients).

16 CAD – coronary artery disease.

17

18 Table 4

19 Analyzed SNPs characteristic – number of genotypes (wild type/alternative
20 heterozygote/alternative homozygote) in studied group (70 patients) and in control group
21 unmatched (597 people) and matched by age and sex (210 people).

1 A – adenine, *APOB* – apolipoprotein B gene, G – guanine, *LDLR* – low density lipoprotein
2 receptor gene, MI – myocardial infarction, *PCSK9* – proprotein convertase subtilisin/kexin
3 type 9 gene, SNP – single nucleotide polymorphism, *SYNE1* - spectrin repeat containing
4 nuclear envelope protein 1 gene.


5

6 Table 5

7 Multivariable regression model included smoking status, BMI and presence of *SYNE1*
8 rs36215567 variant confirmed this SNP as an independent risk factor for premature MI;
9 studied group – 70 patients, control group – 597 people; Fisher’s exact test, *statistically
10 significant.

11 BMI – body mass index, CI – confidence intervals, MI – myocardial infarction, OR – odds
12 ratio, SNP – single nucleotide polymorphism, *SYNE1* - spectrin repeat containing nuclear
13 envelope protein 1 gene.

1



2

3 Figure 1

4 *SYNE1* gene variant rs36215567 (NM_182961.4: c.20396+22A>G) *LDLR* c.667G>A,
 5 *PCSK9* c.658-36G>A, and *APOB* c.12382G>A incidence in the studied group (70 patients)
 6 compared to the control population matched by age and gender (210 people); Fisher's exact
 7 test.

8 *APOB* – apolipoprotein B gene, CI – confidence intervals, G – guanine, *LDLR* – low density
 9 lipoprotein receptor gene, OR – odds ratio, *PCSK9* – proprotein convertase subtilisin/kexin
 10 type 9 gene, SNP – single nucleotide polymorphism, *SYNE1* - spectrin repeat containing
 11 nuclear envelope protein 1 gene.

12

Table 1.

Clinical and haemodynamic characteristics of studied group (70 patients).

CAD – coronary artery disease, LVEF – left ventricle ejection fraction, NSTEMI – non-ST elevation myocardial infarction, SD – standard deviation, STEMI – ST elevation myocardial infarction.

Clinical and haemodynamic characteristics	Number of affected patients
	n (%) mean (±SD)
STEMI	18 (25.7%)
nSTEMI	52 (74.3%)
1-vessel CAD	33 (47.1%)
2-vessel CAD	17 (24.3%)
3-vessel CAD	20 (28.6%)
LVEF mean	51.8% (SD ±8.0)

Table 2.

Anthropometric and biochemical characteristics of studied group (70 patients).

BMI – body mass index, HDL – high density lipoprotein, LDL – low density lipoprotein, SD – standard deviation.

Studied group characteristics	mean (\pmSD)
BMI kg/m ²	28.8 (\pm 3.5)
Total cholesterol mg/dl	202.3 (\pm 3.5)
HDL mg/dl	40.6 (\pm 9.6)
LDL mg/dl	124.0 (\pm 28.9)
Triglycerides mg/dl	164.4 (\pm 63.5)
Glucose mg/dl	108.3 (\pm 19.9)
Creatinine mg/dl	0.9 (\pm 0.2)

Table 3.

CAD risk factors in studied group (70 patients).

CAD – coronary artery disease.

Risk factors	Number of affected patients
	n (%)
Smoking	63 (90%)
Hypertension	44 (62.8%)
Diabetes mellitus	11 (15.7%)
Depression	8 (11.4%)

Table 4:

Analyzed SNPs characteristic – number of genotypes (wild type/alternative heterozygote/alternative homozygote) in studied group (70 patients) and in control group unmatched (597 people) and matched by age and sex (210 people).

A – adenine, *APOB* – apolipoprotein B gene, G – guanine, *LDLR* – low density lipoprotein receptor gene, MI – myocardial infarction, *PCSK9* – proprotein convertase subtilisin/kexin type 9 gene, SNP – single nucleotide polymorphism, *SYNE1* - spectrin repeat containing nuclear envelope protein 1 gene.

Gene	SNP (genotypes)	MI group	Control group (unmatched)	Control group (matched)
<i>SYNE1</i>	rs36215567 (AA/AG/GG)	64/6/0	586/11/0	208/2/0
<i>LDLR</i>	rs11669576 (GG/GA/AA)	61/7/0	541/48/1	198/10/0
<i>PCSK9</i>	rs11800265 (GG/GA/AA)	61/5/0	414/43/1	150/14/0
<i>APOB</i>	rs1801703 (GG/GA/AA)	65/5/0	587/9/0	207/3/0

Table 5:

Multivariable regression model included smoking status, BMI and presence of *SYNE1* rs36215567 variant confirmed this SNP as an independent risk factor for premature MI; studied group – 70 patients, control group – 597 people; Fisher’s exact test, *statistically significant.

BMI – body mass index, CI – confidence intervals, MI – myocardial infarction, OR – odds ratio, SNP – single nucleotide polymorphism, *SYNE1* - spectrin repeat containing nuclear envelope protein 1 gene.

Variable	OR	OR (95% CI)	P value
BMI	1.13	1.05 – 1.23	0.001*
Smoking status	19.40	8.19 – 45.94	<0.001*
<i>SYNE1</i> rs36215567 variant	13.86	1.64 – 117.45	0.016*